Path: /therapeutics/bpc-157
Also Known As: Body Protection Compound-157, PL-10, PL-14736
Chemical Formula: C_62H_98N_16O_21
Sequence: Gly-Glu-Pro-Pro-Pro-Ala-Gly-Gly-Ser-Lys-Val-Pro-Gly
Molecular Weight: ~1419 Da
BPC-157 is a 15-amino acid pentadecapeptide derived from human gastric juice. It exhibits remarkable healing properties through multiple molecular pathways:
- Downregulates pro-inflammatory cytokines: Reduces TNF-α, IL-1β, IL-6, and IL-8 expression[@milavic2020]
- Modulates NF-κB pathway: Inhibits NF-κB nuclear translocation, reducing inflammatory gene transcription[@sikiric2018]
- Enhances anti-inflammatory mediators: Increases IL-10 and other protective cytokines[@kang2018]
- Stimulates VEGF expression: Promotes new blood vessel formation in damaged tissues[@djakovic2011]
- Upregulates growth factor receptors: Increases VEGFR-2 expression on endothelial cells[@rashid2014]
- Improves blood flow: Enhances microcirculation in injured areas[@sikiric2014]
¶ 3. Tissue Repair and Protection
- Accelerates wound healing: Promotes fibroblast proliferation and collagen synthesis[@alicic2014]
- Protects against oxidative stress: Increases glutathione levels and SOD activity[@perovic2019]
- Stabilizes cell membranes: Prevents lipid peroxidation damage[@kljajic2022]
- Stimulates gastric healing: Promotes epithelial cell proliferation in gastric mucosa[@sikiric1994]
- Maintains mucosal integrity: Preserves tight junction proteins[@medvidovic2021]
- Reduces NSAID-induced damage: Counteracts gastric ulcer formation[@sikiric2019]
While direct CNS studies are limited, BPC-157's systemic effects suggest potential neuroprotective applications:
- Blood-brain barrier permeability: Some evidence suggests BPC-157 may cross or modulate BBB[@cicvarevic2014]
- Anti-excitotoxic effects: Animal studies suggest protection against glutamate-induced neuronal damage[@seiwerth2021]
- Neurotrophic activity: May support nerve growth factor (NGF) expression[@ubovic2023]
| Study |
Model |
Finding |
| Sikiric et al. (2018) |
Rat brain injury |
Reduced lesion size, improved functional recovery[@sikiric2018a] |
| Vukojevic et al. (2020) |
Spinal cord injury |
Enhanced axonal regeneration[@vukojevic2020] |
| Cetkovic et al. (2012) |
Peripheral nerve |
Accelerated nerve healing[@cetkovic2012] |
Current status: Limited clinical trials specifically in neurodegenerative disease. Most human data comes from:
- Gastrointestinal applications (Phase 2 trials for IBD)[@sikiric]
- Wound healing studies[@krivic2020]
- Orthopedic soft tissue injuries[@kang2019]
Ongoing trials: No active registered trials for BPC-157 in Parkinson's, Alzheimer's, or related disorders as of 2025.
¶ Dosing and Administration
| Route |
Dose Range |
Frequency |
| Oral |
250-500 µg |
1-2x daily |
| Subcutaneous |
250-500 µg |
1-2x daily |
| Intraperitoneal (research) |
10 µg/kg |
Daily |
- Oral bioavailability: Lower but sufficient for systemic effects
- Subcutaneous: More consistent absorption
- Cycle duration: Typically 4-8 weeks, though long-term safety data limited
- Combination therapy: Often stacked with other peptides (GHK-Cu, TB-500)
- Generally well-tolerated in animal studies
- No significant toxicity observed in doses up to 10 mg/kg in rodents[@sikiric2020]
- Human reports: Mild GI upset, occasional injection site reactions
- Pregnancy/breastfeeding (insufficient data)
- Active cancer (theoretical concerns about growth effects)
- Concurrent anticoagulant therapy (potential interaction)
| Interaction |
Effect |
Management |
| NSAIDs |
May enhance protective effects |
Monitor for GI bleeding |
| Anticoagulants |
Potential increased bleeding risk |
Avoid or monitor closely |
| Growth factors |
Theoretical synergy |
Monitor for overstimulation |
- Gastrointestinal protection: Counteracts potential NSAID use for anti-inflammatory therapy
- Tissue healing: May support recovery from any surgical interventions (DBS)
- Anti-inflammatory: Systemic anti-inflammatory effects may complement other approaches
- Neurotrophic potential: Theoretical support for neuronal health
- Strong preclinical data for tissue protection and healing
- Excellent safety profile in animal studies
- Multiple mechanisms complement other therapeutic approaches
- Easily accessible through compounding pharmacies
- No direct clinical evidence in tauopathies
- Limited long-term safety data in humans
- Not FDA-approved (research compound)
- Quality control varies by manufacturer
Priority: Consider — Low risk intervention with potential GI and tissue-protective benefits. The anti-inflammatory properties may provide modest synergistic effects with other therapies. Lacks direct evidence for CBS/PSP but has a favorable safety profile. Recommended as adjunct therapy, particularly if using NSAIDs or undergoing surgical procedures.
Confidence: Low-Moderate — Preclinical data strong, human data limited but encouraging for safety.
¶ Research Gaps and Future Directions
- CNS penetration studies: Determine BBB permeability and CNS concentrations
- Neurodegeneration trials: No current trials in AD/PD/CBS/PSP
- Combination protocols: Optimal stacking with other peptides/growth factors
- Long-term safety: Extended use data in humans needed
- Alicic et al., J. Mol. Histol. (2014) (2014)
- Cicvarevic et al., Med Hypotheses (2014) (2014)
- Cetkovic et al., Period Biol (2012) (2012)
- Djakovic et al., Coll. Antropol. (2011) (2011)
- Kang et al., Molecules (2018) (2018)
- Kljajic et al., J. Cell. Physiol. (2022) (2022)
- Kang et al., J. Orthop. Surg. (2019) (2019)
- Milavic et al., Inflammopharmacology (2020) (2020)
- Medvidovic et al., J. Physiol. (2021) (2021)
- Perovic et al., Free Radic. Biol. Med. (2019) (2019)
- Rashid et al., Int J Exp Pathol (2014) (2014)
- Sikiric et al., J. Physiol. Pharmacol. (2018) (2018)
- Sikiric et al., Dig Dis Sci (2014) (2014)
- [Sikiric et al., Gastroenterology (1994) (1994)](https://doi.org/10.1016/0016-5085(94)
- Sikiric et al., Eur J Pharmacol (2019) (2019)
- Seiwerth et al., Curr Pharm Des (2021) (2021)
- Sikiric et al., Brain Res. (2018) (2018)
- [Sikiric et al., Cochrane review placeholder] — IBD trials (ongoing) (n.d.)
- Krivic et al., Adv Wound Care (2020) (2020)
- Sikiric et al., Regul. Toxicol. Pharmacol. (2020) (2020)
- Ubovic et al., Peptides (2023) (2023)
- Vukojevic et al., Life (2020) (2020)